赵洋;黄晓婕;刘翠娥;

• 1:首都医科大学附属北京佑安医院

摘要(Abstract)：

宫颈癌发病率居全球女性恶性肿瘤发病率第4位,人乳头瘤病毒感染导致了90%宫颈癌的发生。预防性人乳头瘤病毒疫苗接种已成为预防宫颈癌的有效手段。本文介绍了人乳头瘤病毒的生物学特性以及从有效性、免疫原性、安全性、不同地区应用现状和疫苗接种影响因素方面介绍了预防性人乳头瘤病毒疫苗的临床研究进展。

关键词(KeyWords)： 人乳头瘤病毒;宫颈癌;预防性人乳头瘤病毒疫苗

Abstract:

Keywords:

基金项目(Foundation): 国家“十三五”科技重大专项课题(2017ZX10201101);; 北京市卫生系统高层次卫生技术人才培养计划(2014-3-085);; 北京市属医院科研培育计划(PZ2017013)~~

作者(Authors): 赵洋;黄晓婕;刘翠娥;

DOI: 10.13419/j.cnki.aids.2020.08.33

参考文献(References)：

• [1] de Martel C, Plummer M, Vignat J, et al. Worldwide burden of cancer attributable to HPV by site, country and HPV type[J]. Int J Cancer,2017,141(4):664-670. DOI:10.1002/ijc.30716.
• [2]刘景慧,杨姣,蒿艳蓉.宫颈癌早期预防及疫苗应用的研究进展[J].中国临床新医学, 2019,12(4):377-380.
• [3] Hancock G, Hellner K, Dorrell L. Therapeutic HPV vaccines[J]. Best Practice&Research Clinical Obstetrics&Gynaecology, 2018(47):59-72. DOI:10.1016/j.bpobgyn. 2017.09.008.
• [4] Drolet M, Bénardé, Pérez N, et al. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes:updated systematic review and meta-analysis[J].The Lancet, 2019,394(10197):497-509. DOI:10.1016/S0140-6736(19)30298-3.
• [5] Chen Y, Liu Y, Zhang G, et al. Human papillomavirus L1 protein expressed in Escherichia coli self-assembles into virus-like particles that are highly immunogenic[J]. Virus Research, 2016(220):97-103.DOI:10.1016/j.virusres. 2016.04.017.
• [6] McKee SJ, Bergot A, Leggatt GR. Recent progress in vaccination against human papillomavirus-mediated cervical cancer[J]. Reviews in Medical Virology, 2015(25):54-71. DOI:10.1002/rmv.1824.
• [7] Babiker AY, Eltom FM, Abdalaziz MS, et al. Screening for high risk human papilloma virus(HR-HPV)subtypes, among Sudanese patients with oral lesions[J]. Int J Clin Exp Med, 2013,6(4):275-281.
• [8] Calmon MF, Mota MTDO, Babetoé, et al. Overexpression of ANXA1in penile carcinomas positive for high-risk HPVs[J]. PLoS One,2013,8(1):e53260. DOI:10.1371/journal.pone.0053260.
• [9]麦家豪,马玲国.人乳头状瘤病毒与喉癌的相关性研究现状[J].中华耳鼻咽喉头颈外科杂志, 2019,54(5):385-388.
• [10]胡慧英,于振坤,何双八,等. HPV感染在咽喉部鳞癌及喉乳头状瘤中的分布研究[J].医学研究生学报, 2017,30(12):1264-1267.
• [11] Juckett G, Hartman-Adams H. Human papillomavirus:clinical manifestations and prevention[J]. Am Fam Physician,2010,82(10):1209-1213.
• [12] Zhai L, Tumban E. Gardasil-9:A global survey of projected efficacy[J]. Antiviral Res, 2016(130):101-109. DOI:10.1016/j.antiviral. 2016.03.016.
• [13] Grulich AE, Jin F, Conway EL, et al. Cancers attributable to human papillomavirus infection[J]. Sexual Health, 2010,7(3):244. DOI:10.1071/SH10020.
• [14] Juckett GMM, Hartman-Adams HM. Human Papillomavirus:Clinical Manifestations and Prevention[J]. American Family Physician,2010,82(10):1209-1214.
• [15] Yu Y, Zhang Y, Zhang S. MicroRNA-92 regulates cervical tumorigenesis and its expression is upregulated by human papillomavirus-16 E6 in cervical cancer cells[J]. Oncol Lett,2013,6(2):468-474. DOI:10.3892/ol.2013.1404.
• [16] Vishnoi K, Mahata S, Tyagi A, et al. Human papillomavirus oncoproteins differentially modulate epithelial-mesenchymal transition in 5-FU-resistant cervical cancer cells[J]. Tumor Biology,2016,37(10):13137-13154. DOI:10.1007/s13277-016-5143-6.
• [17] Al-Taei S, Banner R, Powell N, et al. Decreased HPV-specific T cell responses and accumulation of immuno-suppressive influences in oropharyngeal cancer patients following radical therapy[J]. Cancer Immunology, Immunotherapy, 2013,62(12):1821-1830. DOI:10.1007/s00262-013-1488-5.
• [18] Jabbar SF, Park S, Schweizer J, et al. Cervical Cancers Require the Continuous Expression of the Human Papillomavirus Type 16 E7Oncoprotein Even in the Presence of the Viral E6 Oncoprotein[J].Cancer Research, 2012,72(16):4008-4016. DOI:10.1158/0008-5472.CAN-11-3085.
• [19]高燕,岳文涛.人乳头瘤病毒致癌机制及相关疫苗研究进展[J].国际病毒学杂志, 2019,26(1):69-72. DOI:10.3760/cma.j.issn.1673-4092.2019.01.020.
• [20] Stanley M, Pinto LA, Trimble C. Human Papillomavirus Vaccines–Immune Responses[J]. Vaccine, 2012(30):F83-F87. DOI:10.1016/j.vaccine. 2012.04.106.
• [21] Garland SM, Cheung T, McNeill S, et al. Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine[J]. Vaccine,2015,33(48):6855-6864. DOI:10.1016/j.vaccine. 2015.08.059.
• [22]张继红,腾国伟,斗智,等.九价人乳头瘤病毒疫苗接种后保护效果、免疫原性及安全性meta分析[J].中国公共卫生,2019,35(4):491-496.
• [23] Jorma Paavonen DJFX, Xavier Castellsague NSDC, Wim Quint BSPP.Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and18 in young women:an interim analysis of a phase III double-blind,randomised controlled trial[J]. Lancet, 2007.(Epub ahead of print).
• [24] Huh WK, Joura EA, Giuliano AR, et al. Final efficacy,immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years:a randomised,double-blind trial[J]. The Lancet, 2017, 390(10108):2143-2159.DOI:10.1016/S0140-6736(17)31821-4.
• [25] Chow EPF, Machalek DA, Tabrizi SN, et al. Quadrivalent vaccinetargeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme:a retrospective observational study[J]. The Lancet Infectious Diseases,2017,17(1):68-77. DOI:10.1016/S1473-3099(16)30116-5.
• [26] Tabrizi SN, Brotherton JML, Kaldor JM, et al. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia:a repeat cross-sectional study[J].The Lancet Infectious Diseases, 2014,14(10):958-966. DOI:https://doi.org/10.1016/S1473-3099(14)70841-2.
• [27] Bollerup S, Baldur-Felskov B, Blomberg M, et al. Significant Reduction in the Incidence of Genital Warts in Young Men 5 Years into the Danish Human Papillomavirus Vaccination Program for Girls and Women[J]. Sexually Transmitted Diseases, 2016,43(4):238-242.DOI:10.1097/OLQ.0000000000000418.
• [28] Crowe E, Pandeya N, Brotherton JML, et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities:case-control study nested within a population based screening programme in Australia[J]. BMJ, 2014,348(mar04 2):g1458. DOI:10.1136/bmj.g1458.
• [29] Gertig DM, Brotherton JML, Budd AC, et al. Impact of a populationbased HPV vaccination program on cervical abnormalities:a data linkage study[J]. BMC medicine, 2013,11(1):227. DOI:10.1186/1741-7015-11-227.
• [30] Drolet M, Bénardé, Boily M, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes:a systematic review and meta-analysis[J]. The Lancet Infectious Diseases, 2015,15(5):565-580. DOI:10.1016/S1473-3099(14)71073-4.
• [31] Pollock KGJ, Kavanagh K, Potts A, et al. Reduction of low-and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland[J]. British Journal of Cancer,2014,111(9):1824-1830. DOI:10.1038/bjc. 2014.479.
• [32] Powell SE, Hariri S, Steinau M, et al. Impact of human papillomavirus(HPV)vaccination on HPV 16/18-related prevalence in precancerous cervical lesions[J]. Vaccine, 2012,31(1):109-113. DOI:10.1016/j.vaccine. 2012.10.092.
• [33] Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women[J]. N Engl J Med, 2015,372(8):711-723. DOI:10.1056/NEJMoa1405044.
• [34] Van Damme P, Meijer CJLM, Kieninger D, et al. A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men[J]. Vaccine, 2016,34(35):4205-4212. DOI:10.1016/j.vaccine. 2016.06.056.
• [35] Vesikari T, Brodszki N, van Damme P, et al. A Randomized, DoubleBlind, Phase III Study of the Immunogenicity and Safety of a9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine(V503)Versus Gardasil?in 9-15-Year-Old Girls[J]. The Pediatric Infectious Disease Journal, 2015,34(9):992-998. DOI:10.1097/INF.0000000000000773.
• [36] Chen W, Zhao Y, Xie X, et al. Safety of a quadrivalent human papillomavirus vaccine in a Phase 3, randomized, double-blind,placebo-controlled clinical trial among Chinese women during90 months of follow-up[J]. Vaccine, 2019,37(6):889-897. DOI:10.1016/j.vaccine. 2018.12.030.
• [37]勾睿,林蓓.预防性HPV疫苗安全性的系统综述[J].中国实用妇科与产科杂志, 2019,35(7):827-832.
• [38] Human papillomavirus vaccines:WHO position paper, May2017-Recommendations[J]. Vaccine, 2017,35(43):5753-5755. DOI:10.1016/j.vaccine. 2017.05.069.
• [39] Geier DA, Geier MR. Quadrivalent human papillomavirus vaccine and autoimmune adverse events:a case–control assessment of the vaccine adverse event reporting system(VAERS)database[J]. Immunologic Research, 2017,65(1):46-54. DOI:10.1007/s12026-016-8815-9.
• [40] Arnheim-Dahlstrom L, Pasternak B, Svanstrom H, et al. Autoimmune,neurological, and venous thromboembolic adverse events after immunization of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden:cohort study[J]. BMJ,2013,347(oct094):f5906. DOI:10.1136/bmj.f5906.
• [41]张莉,赵方辉.预防性人乳头状瘤病毒疫苗的应用研究进展[J].中华肿瘤杂志, 2018,40(10):724-728. DOI:10.3760/cma.j.issn.0253-3766. 2018.10.002.
• [42] Sabeena S, Bhat PV, Kamath V, et al. Global human papilloma virus vaccine implementation:An update[J]. Journal of Obstetrics and Gynaecology Research, 2018,44(6):989-997. DOI:10.1111/jog.13634.
• [43] Zhang Y, Wang Y, Liu L, et al. Awareness and knowledge about human papillomavirus vaccination and its acceptance in China:a meta-analysis of 58 observational studies[J]. BMC Public Health,2016(16):216. DOI:10.1186/s12889-016-2873-8.
• [44] Oh J, Jeong BY, Yun EH, et al. Awareness of and Attitudes toward Human Papillomavirus Vaccination among Adults in Korea:9-Year Changes in Nationwide Surveys[J]. Cancer Research and Treatment,2018,50(2):436-444. DOI:10.4143/crt.2017.174.
• [45]韩耀风,庄鋆妮,李昀,等.厦门市母亲接受女儿接种HPV疫苗情况及相关因素[J].中华预防医学杂志, 2018, 52(1):38-42. DOI:10.3760/cma.j.issn.0253-9624. 2018.01.008.
• [46]富诗岚,余艳琴,徐慧芳,等.中国大陆人群对人乳头瘤病毒预防性疫苗的认知和态度[J].中国肿瘤临床, 2018,45(23):1220-1224.